The biotechnology company discloses disappointing trial data for two treatments for Duchenne muscular dystrophy. ...

Brazilian planemaker Embraer on Tuesday posted a third-quarter adjusted net income of $54.4 million, down from $221 million a year earlier, citing a hit from extraordinary items such as deferred taxes... ...

Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting disease missed a key goal, deepening concerns about the company's treatment pip... ...

Deutsche Pfandbriefbank (PBB) shares fell further on Tuesday with traders citing no clear driver behind the slump amid markets growing concerned about broader credit conditions. ...

Nintendo has revised its expectations for the Switch 2, projecting sales of 19 million units for the fiscal year ending March 2026, up from the earlier forecast of 15 million. The Japanese gaming comp... ...

在安全性方面，该公司的整体研究呈现出多年来在外显子跳跃疗法中观察到的良好且稳定的安全性特 征。 Sarepta 还报告称，其第三季度营收小幅下降了约14.5%，总计3.99亿美元，但较华尔街分析师普遍预期 高出6237万美元。 智通财经APP获悉，在针对杜氏肌营养不良症(DMD)的两种基因疗法AMONDYS 45(casimersen)以及 VYONDYS 53(golodirsen)的后期临床试验未能达到其主要目标后，专注于罕见病疗法的全球知名生物 科技公司Sarepta Therapeutics(SRPT.US)的股价大幅下跌，该股在美股盘后交易中一度暴跌超过39%。 据了解，这项临床试验纳入了225名年龄在6至13岁之间的男孩群体，他们具有一种可以通过跳跃45号或 53号外显子来处理的特定杜氏变异。 这家生物科技公司表示，这项历时九年的研究曾经由于新冠疫情而面临严峻挑战，新冠疫情严重影响了 受试者以及整体试验结果。 杜氏肌营养不良症通常在儿童早期开始，并随着时间的推移而恶化，使行走、呼吸和其他日常活动变得 越来越困难。 由于监管审查力度近年来持续加大，以及与该公司另一项基因疗法Elevidys相关的三名 ...

Sarepta's stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints. ...

Sarepta Therapeutics (NasdaqGS:SRPT) Q3 2025 Earnings Call November 03, 2025 04:30 PM ET Speaker1Good afternoon and welcome to Sarepta's third quarter 2025 financial results conference call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Tam Thornton, Director of Investor Relations. Please go ahead.Speaker7Thank you. Thank you all for joining today's call. Earlier this afternoon, we released our financial results for the third quarter of 2025. The press release an ...

November 3, 2025 Q3 2025 Earnings Conference Call Patients can't wait for the next breakthrough in medical research. So neither will we. Doug Ingram CEO Louise Rodino-Klapac, PhD President, R&D and Technical Operations Patrick E. Moss, PharmD Executive Vice President, Chief Commercial Officer Ryan H. Wong Executive Vice President, Chief Financial Officer DILLON Living with Duchenne muscular dystrophy ©SAREPTA THERAPEUTICS, INC. 2025. ALL RIGHTS RESERVED. 1 Forward-looking statements In order to provide Sare ...

Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal. ...